Professor Newsome runs the metabolic services at the Liver Unit at King’s College Hospital London which includes a large multi-disciplinary clinic for patients with non-alcoholic fatty liver disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM.

He is the Co-ordinating Investigator for several global NAFLD studies. He chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of the European Association for the Study of the Liver (EASL).

He developed the FAST score for identifying patients with at-risk NASH and also co-led the global nomenclature process that changed the name and definition of NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD). He was Director of the Midlands & Wales ATTC in its first two rounds of IUK funding. His laboratory has focussed on the role of cell therapy in liver injury. He has established three cutting edge clinical trials which he is the Chief Investigator on: One of these, REALISTIC, is the largest clinical trial of haematopoietic stem cell therapy in patients with liver cirrhosis in Europe/US was published in Lancet Gastroenterology & Hepatology.

He co-ordinates the MERLIN (EU FP7) consortium which includes a clinical trial of mesenchymal stromal cells in patients with primary sclerosing cholangitis (PSC) and also the POLARISE basket trial in patients with PSC, rheumatoid arthritis, Crohn’s disease and lupus nephritis. He is National Clinical Lead for the Advanced Therapy Treatment Centres He is Senior Editor at the Journal of Hepatology